Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen

Delcath Systems (NASDAQ:DCTH) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Several other research analysts have also recently issued reports on the company. Stephens dropped their price target on Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Evercore set a $27.00 price objective on Delcath Systems in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Delcath Systems in a research report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Delcath Systems in a report on Friday, January 9th. Finally, BTIG Research decreased their price target on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Thursday. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Delcath Systems Trading Down 1.1%

Shares of NASDAQ DCTH opened at $8.90 on Friday. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $18.23. The firm has a 50-day moving average of $9.98 and a two-hundred day moving average of $10.20. The company has a market capitalization of $314.26 million, a price-to-earnings ratio of 127.14 and a beta of 0.37.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Thursday, March 5th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Delcath Systems had a net margin of 3.17% and a return on equity of 2.70%. The business had revenue of $20.73 million for the quarter, compared to the consensus estimate of $20.35 million. As a group, research analysts predict that Delcath Systems will post -0.79 earnings per share for the current year.

Delcath Systems declared that its board has authorized a stock buyback plan on Thursday, November 20th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 8.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of Delcath Systems

Several institutional investors have recently made changes to their positions in DCTH. California State Teachers Retirement System purchased a new position in Delcath Systems during the second quarter valued at approximately $26,000. Russell Investments Group Ltd. acquired a new stake in shares of Delcath Systems during the 3rd quarter valued at $29,000. Tower Research Capital LLC TRC purchased a new position in shares of Delcath Systems during the 2nd quarter valued at $40,000. Ameritas Investment Partners Inc. purchased a new position in shares of Delcath Systems during the 2nd quarter valued at $42,000. Finally, Legal & General Group Plc acquired a new position in shares of Delcath Systems in the second quarter worth $46,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Key Delcath Systems News

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Company reported Q4 and full‑year 2025 results with Q4 revenue of $20.7M and full‑year revenue of $85.2M; EPS of ($0.05) beat consensus by $0.01 — evidence of improving commercial execution. BusinessWire Release
• Positive Sentiment: Management is targeting at least $100M in revenue for 2026 and plans to expand to ~40 treatment centers, signaling a clear growth roadmap and potential material revenue upside if execution continues. Seeking Alpha
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to ~$100.0M (effectively in line with consensus ~100.1M); guidance confirms the growth target but leaves little upside vs. street estimates absent faster center rollout or higher per‑center revenue. MarketBeat Earnings
• Neutral Sentiment: BTIG cut its price target from $23 to $19 but kept a “buy” rating—still implying substantial upside from current levels, though the downgrade signals more conservative near‑term expectations from at least one sell‑side shop. Street Insider

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.